Procaps Group Sa Stock Price, News & Analysis

Procaps Group (NASDAQ: PROC) has announced preliminary financial estimates for 2022, projecting revenues between $405-$415 million with an estimated Adjusted EBITDA of $75-$80 million, reflecting a decline due to currency devaluation and supply chain issues. The company plans a $15 million cost reduction strategy aimed at improving margins and profitability. A share repurchase program of $5 million has also been initiated to enhance shareholder value. Moving forward, Procaps anticipates a revenue growth of over 10% in 2023, supported by strategic investments and new product launches, despite facing challenges from recent economic conditions.

Procaps Group (NASDAQ: PROC) announced the appointment of Alberto Eguiguren Correa to its Board of Directors, replacing Alejandro Weinstein, effective immediately. Eguiguren brings over 20 years of experience in global healthcare and pharma, having held board positions in multiple companies and extensive expertise in strategic planning and mergers. This change comes as Weinstein decided to step down due to disagreements over the company’s strategic priorities. The new appointment aims to enhance Procaps’ growth trajectory amid ongoing product development and market expansion efforts.

Procaps Group terminated its agreement to acquire Grupo Somar due to legal issues in Mexico that prevented the transaction's completion. A court issued an Embargo Precautorio affecting Grupo Somar's shares, leading to the indefinite delay of the acquisition initially expected to close by December 31, 2022. Despite this setback, Procaps remains open to discussions and emphasizes its commitment to its growth strategy. The company will present its 2023 value creation plan at the upcoming J.P. Morgan Healthcare Conference on January 10, 2023.

Procaps Group, S.A. (NASDAQ: PROC) will present its 2023 growth plans at the J.P. Morgan Healthcare Conference on January 10, 2023, at 8:00 am PST. CEO Ruben Minski highlighted the challenges faced in late 2022 due to currency depreciation and inflation, emphasizing the need for strategic adjustments to safeguard shareholder value. Despite difficulties in Q4, he remains optimistic about the company's long-term prospects. Procaps is a major player in the healthcare sector, providing pharmaceutical and nutraceutical products in over 50 countries.

Procaps (NASDAQ: PROC) updates on its acquisition of Grupo Somar, initially set to close on October 14, 2022. A court in Mexico City issued an Embargo Precautorio affecting certain shares of Grupo Somar, causing delays. The company is exploring alternatives with sellers, although the timing for resolution remains uncertain and outside their control. Despite this setback, Procaps maintains that the acquisition's strategic rationale is attractive and anticipates potential synergies and growth opportunities once the Embargo is resolved.

Procaps Group reported a 15% increase in constant currency net revenues year-over-year for the first nine months of 2022, totaling $309 million, with a 3% increase in 3Q22 revenues at $110 million. Strong demand for RX, OTC, and CDMO products contributed to an impressive 61% gross margin. The company launched over 140 products in 2022 and is on track to finalize the Grupo Somar acquisition by year-end. However, ongoing currency devaluation led to an $8 million revenue loss in 3Q22. The company anticipates challenges from global economic conditions but remains optimistic about growth in 2023.

Procaps Group (NASDAQ: PROC) will report its third-quarter results for the period ending September 30, 2022, on November 14, 2022, after market close. A conference call and webcast will be held on November 16, 2022, at 04 p.m. ET.

Participants can join the call using the toll-free number 1-844-204-8586 or the international number 1-412-317-6346. The conference call will be available for replay until November 25, 2022. Procaps is a prominent healthcare and pharmaceutical company operating in 13 countries and reaching over 50 countries worldwide.